GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Inventories, Finished Goods

DaVita (BSP:DVAI34) Inventories, Finished Goods : R$0 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is DaVita Inventories, Finished Goods?


DaVita Inventories, Finished Goods Historical Data

The historical data trend for DaVita's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Inventories, Finished Goods Chart

DaVita Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DaVita Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

DaVita Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


DaVita (BSP:DVAI34) Business Description

Traded in Other Exchanges
Address
2000 16th Street, Denver, CO, USA, 80202
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

DaVita (BSP:DVAI34) Headlines

No Headlines